Massive Bio vs Paradigm Health
The two strongest evidenced trial matching companies, and they differ on where the matching happens. Paradigm deploys inside the provider record system, reasons over full text notes with language models rather than structured prefilters, and pairs the software with recruitment staff across a network spanning dozens of states and well over a hundred provider organisations. Massive Bio matches without requiring an integration at all, covering oncology and haematology against a very large active trial list, with every match audited by certified oncology case managers and rare peer reviewed prospective evidence behind it. For a health system building trial capacity into routine oncology care, Paradigm is the deeper answer and the longer implementation. For a site or a patient who needs matching to work this month, Massive Bio removes the integration entirely, which is usually what kills these projects.
- It matches without needing an integration at all, which removes the longest pole in most trial matching deployments and lets a site or a patient start now rather than after an IT project.
- Rare peer reviewed prospective evidence for a matching product, published in an oncology real world data journal, against a category where most matching claims are retrospective and vendor run.
- Every generated match is audited by certified oncology case managers before it is used, so the human is structurally in the path rather than nominally responsible for it.
- The eligibility reasoning is done by language models over full text notes rather than structured prefilters alone, and the company published a direct comparison making that case rather than asserting it.
- Network reach is specific and verifiable, spanning dozens of states and well over a hundred provider organisations including designated cancer centres, which is the constraint that actually determines whether a patient finds a trial.
- It deploys inside the provider record system and pairs the software with recruitment staff, so the site is not left to convert matches into enrolments on its own.
Side by Side
| Axis | M Massive Bio |
P Paradigm Health |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
Trial matching carries a documentation bias that neither vendor fully addresses: a patient whose record is thin, whose care is fragmented across systems, or whose notes are written in less structured language will match less often regardless of clinical eligibility, and that population overlaps with the one trials already under enrol. Neither vendor publishes a security attestation or trust centre, and neither publishes pricing.
Paradigm's business associate status is structurally required and nothing is published on it. Massive Bio's model documentation and bias evaluation were not located, and its patient facing route raises a separate question about who is paying for a match a patient found for themselves.